XCUR-FXN–Friedreich’s Ataxia
Exicure remains committed to maintaining its development plans and to pursuing its business strategy in the best interests of its stockholders as well as the patients it looks to serve; however, it acknowledges that, at this point in time, it is unable to determine the potential impact of the asserted claim on its research and development activities or the timing of completion of its current research and development of its XCUR-FXN preclinical program for the treatment of FA, as the investigation of the asserted claim remains ongoing.
Friday, November 19, 2021
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress
Published : Friday, November 19, 2021, ACROFAN=Businesswire.
